Who are Intravenous Levonadifloxacin/Linezolid Infusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oral Levonadifloxacin/Linezolid Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-levonadifloxacin-linezolid-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Intravenous Levonadifloxacin/Linezolid Infusion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous Levonadifloxacin/Linezolid Infusion (Intravenous Levonadifloxacin/Linezolid Infusion) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone/Oxazolidinone combination antibiotic. Area: Infectious Disease.

phase 3 Fluoroquinolone/Oxazolidinone combination antibiotic Bacterial DNA gyrase, topoisomerase IV, 50S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous Levonadifloxacin/Linezolid Infusion (Intravenous Levonadifloxacin/Linezolid Infusion) — Wockhardt. This combination drug pairs a fluoroquinolone antibiotic (levonadifloxacin) that inhibits bacterial DNA gyrase with linezolid, an oxazolidinone that inhibits bacterial protein synthesis, to provide broad-spectrum coverage against gram-positive and gram-negative bacteria.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravenous Levonadifloxacin/Linezolid Infusion TARGET	Intravenous Levonadifloxacin/Linezolid Infusion	Wockhardt	phase 3	Fluoroquinolone/Oxazolidinone combination antibiotic	Bacterial DNA gyrase, topoisomerase IV, 50S ribosomal subunit
Oral Levonadifloxacin/Linezolid Tablet	Oral Levonadifloxacin/Linezolid Tablet	Wockhardt	phase 3	Fluoroquinolone/Oxazolidinone combination antibiotic	DNA gyrase, topoisomerase IV, 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone/Oxazolidinone combination antibiotic class)

Wockhardt · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous Levonadifloxacin/Linezolid Infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-levonadifloxacin-linezolid-infusion. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab